Ohguri Takayuki, Itamura Hirohide, Tani Subaru, Shiba Eiji, Yamamoto Junkoh
Department of Therapeutic Radiology, Hospital of the University of Occupational and Environmental Heath, Kitakyushu, Japan.
Department of Neurosurgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Radiat Oncol. 2025 Jan 9;20(1):4. doi: 10.1186/s13014-024-02579-3.
In this retrospective study, we aimed to evaluate the efficacy and incidence of radiation-induced brain necrosis (RBN) after volumetric modulated arc therapy-based stereotactic irradiation (VMAT-STI) for brain metastases.
In the 220 brain metastatic lesions included between January 2020 and June 2022, there were 1-9 concurrently treated lesions (median 1). A biologically effective dose (BED)10 of 80 Gy and a reduced BED10 of 50 Gy were prescribed to the gross tumor volume (GTV) and planning target volume (PTV) (PTV = GTV + 3 mm) margins, respectively. The number of fractions was adjusted from 3 to 15 to accommodate different GTV sizes; for larger tumor volumes, this was increased while maintaining the BED10 values comparable to those for GTV and PTV margins.
Of the total patients, 16 (7%) exhibited locally progressive lesions; local tumor recurrence was observed in 2 (1%) patients, while RBN was noted in 14 (6%) patients. RBN was significantly more prevalent in the deep white matter around the lateral ventricles (DWM-LV) than in other sites, occurring in 9/22 (41%) lesions of metastases in the DWM-LV. The 2-year actuarial incidence risk of developing RBN was significantly higher in the DWM-LV (69%) than at other sites (5%).
The recurrence rate of brain metastases was low, and the incidence of RBN was lower in tumor sites other than the DWM-LV. However, the frequency of RBN was significantly higher in the DWM-LV region. Additional VMAT-STI-prescribed dose protocols are necessary to reduce RBN incidence in DWM-LVs.
在这项回顾性研究中,我们旨在评估基于容积调强弧形放疗的立体定向放射治疗(VMAT-STI)治疗脑转移瘤后放射性脑坏死(RBN)的疗效和发生率。
纳入2020年1月至2022年6月期间的220个脑转移瘤病灶,同时治疗的病灶有1 - 9个(中位数为1个)。分别对大体肿瘤体积(GTV)和计划靶体积(PTV)(PTV = GTV + 3 mm)边缘规定80 Gy的生物等效剂量(BED)10和50 Gy的降低BED10。分割次数根据不同的GTV大小从3次调整到15次;对于较大的肿瘤体积,分割次数增加,同时保持BED10值与GTV和PTV边缘的BED10值相当。
在所有患者中,16例(7%)出现局部进展性病灶;2例(1%)患者观察到局部肿瘤复发,14例(6%)患者出现RBN。RBN在侧脑室周围深部白质(DWM-LV)比在其他部位更普遍,在DWM-LV转移瘤的9/22(41%)个病灶中出现。DWM-LV发生RBN的2年精算发病率风险(69%)显著高于其他部位(5%)。
脑转移瘤的复发率较低,除DWM-LV外的肿瘤部位RBN的发生率较低。然而,DWM-LV区域RBN的发生率显著更高。需要额外的VMAT-STI规定剂量方案来降低DWM-LV中RBN的发生率。